Highlights

  • EBR Systems (ASX:EBR) has secured ISO 13485 certification for its new Santa Clara Manufacturing facility.
  • The site includes automated assembly equipment expected to materially increase WiSE System production capacity.
  • The certification supports manufacturing scale-up but does not represent a new regulatory approval or Revenue event.
  • FDA Facility approval, implant growth and reimbursement progress remain the main milestones to watch.

EBR Systems (ASX:EBR) has reached an important manufacturing milestone as it continues the US commercial rollout of its WiSE System.

In early September 2026, the company announced that its new manufacturing facility in Santa Clara, California, had achieved ISO 13485 certification, the international quality management standard used across the medical device industry.

For a company still scaling a newly commercialised device, the significance lies less in the certificate itself and more in what it enables: a larger, more automated production base designed to support higher implant volumes.

Automation replaces hands

The Santa Clara facility incorporates automated assembly equipment intended to replace several processes that were previously performed manually.

According to EBR Systems (ASX:EBR), the new equipment is expected to increase WiSE System production capacity by approximately 500%.

The facility replaces the company’s previous Sunnyvale manufacturing operation.

That shift matters because medical device commercialisation requires more than regulatory approval. The company must also demonstrate that it can manufacture consistently, at scale and within tightly controlled quality standards.

ISO 13485 certification supports that process by confirming that the facility’s quality management systems meet an internationally recognised medical-device standard.

What the WiSE System actually is

EBR Systems (ASX:EBR) is focused on the WiSE System, a leadless left ventricular endocardial pacing device used in cardiac resynchronisation therapy for heart failure patients.

The implant measures approximately 2.8 millimetres in diameter and 9.2 millimetres in length.

Unlike conventional systems that rely on a pacing lead placed through the coronary sinus, WiSE is designed to provide wireless pacing from inside the heart.

The device received US Food and Drug Administration approval in 2025 and is currently commercialised in the United States.

That means EBR has already passed a major regulatory hurdle. The focus now is increasingly on execution: physician training, hospital adoption, reimbursement, manufacturing output and procedure growth.

Why capacity matters now

Manufacturing capacity is becoming more relevant as commercial activity expands.

In its August 2026 half-year update, EBR Systems (ASX:EBR) reported 117 total procedures, including more than 100 commercial implants.

The company also reported 90 trained physicians across 30 US sites and agreements with major hospital networks.

This expanding clinical footprint creates a corresponding need for reliable product supply.

If procedure volumes rise faster than manufacturing output, production can become a constraint on revenue growth.

That is why the Santa Clara facility and its automated manufacturing equipment form an important part of the broader commercialisation strategy.

The company also reported cash and investments of US$89.5 million at 30 June 2026, supported by a fully underwritten A$150 million Capital raising.

That funding provides additional resources for commercial expansion, manufacturing scale-up and ongoing regulatory and reimbursement work.

Reimbursement is progressing too

Manufacturing is only one part of the commercial equation.

Reimbursement remains another major Factor determining how quickly new medical technologies gain adoption.

EBR previously secured Medicare New Technology Add-on Payment and Transitional Pass-Through reimbursement support for the WiSE System.

The Centers for Medicare & Medicaid Services has also begun a National Coverage Determination process under its Transitional Coverage for Emerging Technologies pathway.

Broader coverage could improve access to the device across more eligible patients and treatment centres.

However, reimbursement processes can take time, and the ultimate outcome remains separate from the manufacturing milestone.

A certificate is not an approval

The ISO 13485 certification should be viewed carefully.

It represents third-party confirmation of the company’s manufacturing quality management system.

It is not a new FDA clearance for the WiSE System, not a reimbursement determination and not evidence of additional revenue.

The next significant manufacturing-related step remains the FDA Pre-Approval Inspection of the Santa Clara facility, which is scheduled for September 2026.

EBR has indicated that it expects facility approval by the end of 2026.

Until that process is completed, the increased production capacity remains prospective rather than fully available to the US commercial market.

The stated 500% capacity increase therefore reflects the potential of the new automated operation rather than proven commercial output.

Other execution risks remain

EBR Systems (ASX:EBR) is still a single-product medical device company operating through an early commercialisation phase.

That creates concentration risk because the company’s near-term growth depends heavily on adoption of the WiSE System.

The company has also previously disclosed a Cybersecurity incident and has been working through related regulatory review.

Separately, it has addressed implant complications that were characterised as isolated and manageable.

These issues do not negate the commercial progress made to date, but they reinforce the importance of regulatory execution, clinical performance and operational discipline.

The Business also remains cash-consuming, with the recent capital raising providing funding to support continued expansion.

What to watch

The first milestone is the FDA Pre-Approval Inspection of the Santa Clara facility.

A successful outcome would allow EBR to move closer to using the automated production line at commercial scale.

The second is implant growth.

Higher manufacturing capacity will only matter financially if it translates into more procedures and increased revenue rather than excess inventory.

The third is reimbursement.

Progress on the CMS coverage determination could broaden access and support adoption across a larger patient population.

For EBR Systems (ASX:EBR), ISO certification is an enabling milestone rather than an end point. The more important test is whether manufacturing readiness, reimbursement progress and physician adoption combine to support a sustained increase in commercial WiSE procedures.